During the second week of September, child Covid-19 cases hit 243,000 in the United States. This is the second highest number of new cases in children since the pandemic began. In the most recent study to try and prevent the spread of Covid-19, 2,200 children, ages 5 to 11 were vaccinated with Pfizer-BioNTech. Pfizer reported the vaccine as safe and generating a “robust” immune response. The study was based off two 10 microgram shots, given three weeks apart. This is about a third of dosage used in an adult shot with an immune response and side effects very comparable to the results found in the study of the 16 to 25-year-olds.
Pfizer is submitting the results to the FDA, for approval. Based off the vaccine for 12-to 15-year-olds, the FDA could approve before Halloween. Soon the FDA is also going to be issuing a decision on which groups will be eligible for a booster shot of the Pfizer vaccine. As of now only those 65 and older have been approved for the booster.
The next study Pfizer is working on is testing the vaccine on children from 6 months to 5 years old, with possible results ready as soon as end of October.